Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Clonazepam

Classification: B

Drug products: Iktorivil®, Rivotril

ATC code: N03AE01

Substances: clonazepam

Summary

Controlled studies on differences between men and women in effect, safety, or pharmacokinetics of clonazepam are lacking.

Additional information

Pharmacokinetics and dosing

Clearance of clonazepam is similar in men and women [1]. No studies with a clinically relevant sex analysis regarding the dosing of clonazepam have been found.

Effects

Effectiveness of clonazepam in the treatment of panic disorder has been studied in clinical trials by the pharmaceutical company. Subgroup analysis did not indicate that there were any differences in treatment outcomes based on patient’s race or sex [1, 2].

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of clonazepam have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Updated: 2020-08-28

Date of litterature search: 2019-09-24

References

  1. Iktorivil (klonazepam). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2018-05-14, cited 2019-09-24].
  2. Klonopin (clonazepam). DailyMed [www]. US National Library of Medicine. [updated 2018-12-07, cited 2019-09-24]. Länk
  3. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.] länk

Authors: Linnéa Karlsson Lind

Reviewed by: Mia von Euler, Carl-Olav Stiller, Diana Rydberg

Approved by: Karin Schenck-Gustafsson